Hematologic Effects of Linezolid: Summary of Clinical Experience
Open Access
- 1 August 2002
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (8), 2723-2726
- https://doi.org/10.1128/aac.46.8.2723-2726.2002
Abstract
Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at ≥2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.This publication has 17 references indexed in Scilit:
- Linezolid versus Vancomycin for the Treatment of Methicillin‐ResistantStaphylococcus aureusInfectionsClinical Infectious Diseases, 2002
- Linezolid and Reversible MyelosuppressionJAMA, 2001
- Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter StudyClinical Infectious Diseases, 2001
- Drug-Induced ThrombocytopeniaAnnals of Internal Medicine, 1998
- Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial InfectionsJournal of Medicinal Chemistry, 1996
- Cephalosporin‐induced hemolysis: A case report and review of the literatureAmerican Journal of Hematology, 1992
- Platelet-Mediated Bleeding Caused by Broad-Spectrum PenicillinsThe Journal of Infectious Diseases, 1987
- Adverse Reactions Associated with the Use of Oral Penicillins and CephalosporinsMedical Clinics of North America, 1983
- Nafcillin-induced platelet dysfunction and bleedingAntimicrobial Agents and Chemotherapy, 1983
- Drug-Induced AnaemiasDrugs, 1976